SCHEMBL6311375

SCHEMBL6311375

Cc1cccc(-c2ccc3ccccc3c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
HSD17B1 P14061 2/20 0.59
HSD17B2 P37059 2/20 0.59
MAPK14 Q16539 1/20 0.52
ESR1 P03372 3/20 0.52
ESR2 Q92731 3/20 0.52
CYP17A1 P05093 1/20 0.50
CYP19A1 P11511 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
ALOX5 P09917 1/20 0.50
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22373751 0.88 RAB9A (0.58) CYP2A6TDP1HSD17B1HSD17B2MAPK14
SCHEMBL17996026 0.86 CYP2A6 (0.81) CYP2A6TDP1HSD17B1HSD17B2ESR1
SCHEMBL21201617 0.86 CYP2A6 (0.58) CYP2A6TDP1HSD17B1HSD17B2MAPK14
SCHEMBL4546992 0.86 CTRC (0.51) CYP2A6TDP1HSD17B1HSD17B2MAPK14
SCHEMBL18731958 0.85 RAB9A (0.54) CYP2A6TDP1HSD17B1HSD17B2MAPK14
SCHEMBL29629004 0.85 TDP1 (0.58) CYP2A6TDP1HSD17B1HSD17B2ESR1
SCHEMBL18731959 0.85 CTRC (0.57) CYP2A6TDP1HSD17B1HSD17B2MAPK14
SCHEMBL839035 0.84 CYP2A6 (0.56) CYP2A6TDP1HSD17B1HSD17B2ESR1
SCHEMBL22373729 0.84 CYP1A1 (0.54) CYP2A6TDP1MAPK14CYP1A2CYP3A4
SCHEMBL18260215 0.84 HSD17B1 (0.71) HSD17B1HSD17B2ESR1ESR2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070782-A1 METHOD FOR SYNTHESIZING BORONATE ESTER COMPOUND, SODIUM SALT OF BORONATE ESTER COMPOUND, AND METHOD FOR SYNTHESIZING THE SAME KOBELCO ECO-SOLUTIONS CO., LTD. (JP) 2021-03-11 US disclosed
EP-3741764-A1 SYNTHESIS METHOD FOR BORONIC ACID ESTER COMPOUND, AND SODIUM SALT OF BORONIC ACID ESTER COMPOUND AND SYNTHESIS METHOD THEREFOR Kobelco Eco-Solutions Co., Ltd (JP) 2020-11-25 EP disclosed
US-6924301-B1 Composition for treating or preventing arrhythmia SHIONOGI & CO., LTD. (JP) 2005-08-02 US disclosed
EP-0976748-B1 PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2003-12-03 EP disclosed
EP-1240906-A1 PREVENTIVES OR REMEDIES FOR ARRHYTHMIA SHIONOGI & CO., LTD. (JP) 2002-09-18 EP disclosed
US-6147100-A ANTIINFLAMMATORY AGENTS SHIONOGI & CO., LTD. (JP) 2000-11-14 US disclosed
EP-0976748-A1 PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070782-A1 METHOD FOR SYNTHESIZING BORONATE ESTER COMPOUND, SODIUM SALT OF BORONATE ESTER COMPOUND, AND METHOD FOR SYNTHESIZING THE SAME BRSK1, BRSK2, BRI3BP CYP2A6 1680/4885TDP1 2918/4885HSD17B1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.